FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W82109857> ?p ?o ?g. }

• W82109857 endingPage "3137" @default.
• W82109857 startingPage "3132" @default.
• W82109857 abstract "Abstract 4-Hydroperoxycyclophosphamide (4-HC), a commonly used marrow-purging agent, is active against many tumors, but is also toxic to normal marrow progenitors. Amifostine (WR-2721) is a sulfhydryl compound with chemoprotectant activity. Preclinical studies using suspensions of bone marrow and breast cancer cells demonstrated that ex vivo treatment with amifostine followed by 4-HC resulted in protection of marrow progenitors, with no compromise in the antitumor effect of 4-HC. This fact stimulated the development of a clinical trial. Bone marrow was harvested from 15 poor-prognosis breast cancer patients and randomly assigned to ex vivo treatment with amifostine followed by 4-HC (amifostine + 4-HC), or treatment with 4-HC alone. High-dose chemotherapy was then administered followed by infusion of the purged autologous bone marrow support (ABMS). Leukocyte engraftment, defined as a white blood cell count > or = 1 x 10(9)/L, was achieved in an average of 26 days for patients whose marrow was purged with amifostine + 4-HC versus 36 days for patients whose marrow was purged with 4-HC alone (P = .032). The average number of platelet transfusions (12 v 29; P = .017) and days of antibiotic therapy (28 v 40; P = .012) were significantly less for patients whose marrow was exposed to amifostine + 4-HC, compared with 4-HC alone. Unpurged backup marrow fractions were infused into three patients whose marrow was purged with 4-HC alone, because of inadequate marrow recovery. None of the patients who received amifostine + 4-HC-purged marrow required a backup marrow fraction. Complete remissions were achieved in 83% of patients with measurable disease, with no difference between the two cohorts. Forty- three percent of patients remained alive and progression-free at a mean of 13 months posttransplant. There was no significant difference in the rate or pattern of relapse for patients whose marrow was purged with amifostine + 4-HC compared with those whose marrow was purged with 4-HC alone. Ex vivo treatment of marrow with amifostine significantly shortens the time to marrow recovery, thereby reducing the risk of myelosuppressive complications in breast cancer patients receiving high- dose chemotherapy and 4-HC-purged ABMS. Since supportive care requirements are also significantly decreased, amifostine may reduce the cost of such therapy." @default.
• W82109857 created "2016-06-24" @default.
• W82109857 creator A5007458418 @default.
• W82109857 creator A5023136222 @default.
• W82109857 creator A5027320590 @default.
• W82109857 creator A5029186084 @default.
• W82109857 creator A5050109382 @default.
• W82109857 creator A5051544642 @default.
• W82109857 creator A5055885795 @default.
• W82109857 creator A5060562909 @default.
• W82109857 creator A5062682753 @default.
• W82109857 creator A5067595997 @default.
• W82109857 creator A5068382355 @default.
• W82109857 creator A5071526808 @default.
• W82109857 creator A5083819375 @default.
• W82109857 creator A5090814068 @default.
• W82109857 date "1994-06-01" @default.
• W82109857 modified "2023-10-16" @default.
• W82109857 title "Amifostine (WR-2721) shortens the engraftment period of 4- hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support" @default.
• W82109857 doi "https://doi.org/10.1182/blood.v83.11.3132.3132" @default.
• W82109857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8193351" @default.
• W82109857 hasPublicationYear "1994" @default.
• W82109857 type Work @default.
• W82109857 sameAs 82109857 @default.
• W82109857 citedByCount "57" @default.
• W82109857 countsByYear W821098572018 @default.
• W82109857 countsByYear W821098572023 @default.
• W82109857 crossrefType "journal-article" @default.
• W82109857 hasAuthorship W82109857A5007458418 @default.
• W82109857 hasAuthorship W82109857A5023136222 @default.
• W82109857 hasAuthorship W82109857A5027320590 @default.
• W82109857 hasAuthorship W82109857A5029186084 @default.
• W82109857 hasAuthorship W82109857A5050109382 @default.
• W82109857 hasAuthorship W82109857A5051544642 @default.
• W82109857 hasAuthorship W82109857A5055885795 @default.
• W82109857 hasAuthorship W82109857A5060562909 @default.
• W82109857 hasAuthorship W82109857A5062682753 @default.
• W82109857 hasAuthorship W82109857A5067595997 @default.
• W82109857 hasAuthorship W82109857A5068382355 @default.
• W82109857 hasAuthorship W82109857A5071526808 @default.
• W82109857 hasAuthorship W82109857A5083819375 @default.
• W82109857 hasAuthorship W82109857A5090814068 @default.
• W82109857 hasBestOaLocation W821098571 @default.
• W82109857 hasConcept C121608353 @default.
• W82109857 hasConcept C126322002 @default.
• W82109857 hasConcept C201750760 @default.
• W82109857 hasConcept C2776694085 @default.
• W82109857 hasConcept C2779387952 @default.
• W82109857 hasConcept C2780007613 @default.
• W82109857 hasConcept C28328180 @default.
• W82109857 hasConcept C530470458 @default.
• W82109857 hasConcept C54355233 @default.
• W82109857 hasConcept C71924100 @default.
• W82109857 hasConcept C86803240 @default.
• W82109857 hasConceptScore W82109857C121608353 @default.
• W82109857 hasConceptScore W82109857C126322002 @default.
• W82109857 hasConceptScore W82109857C201750760 @default.
• W82109857 hasConceptScore W82109857C2776694085 @default.
• W82109857 hasConceptScore W82109857C2779387952 @default.
• W82109857 hasConceptScore W82109857C2780007613 @default.
• W82109857 hasConceptScore W82109857C28328180 @default.
• W82109857 hasConceptScore W82109857C530470458 @default.
• W82109857 hasConceptScore W82109857C54355233 @default.
• W82109857 hasConceptScore W82109857C71924100 @default.
• W82109857 hasConceptScore W82109857C86803240 @default.
• W82109857 hasIssue "11" @default.
• W82109857 hasLocation W821098571 @default.
• W82109857 hasOpenAccess W82109857 @default.
• W82109857 hasPrimaryLocation W821098571 @default.
• W82109857 hasRelatedWork W1966864247 @default.
• W82109857 hasRelatedWork W2138086170 @default.
• W82109857 hasRelatedWork W2276327453 @default.
• W82109857 hasRelatedWork W2347272611 @default.
• W82109857 hasRelatedWork W2361592813 @default.
• W82109857 hasRelatedWork W2376538688 @default.
• W82109857 hasRelatedWork W2390642283 @default.
• W82109857 hasRelatedWork W3030665462 @default.
• W82109857 hasRelatedWork W4231590606 @default.
• W82109857 hasRelatedWork W82109857 @default.
• W82109857 hasVolume "83" @default.
• W82109857 isParatext "false" @default.
• W82109857 isRetracted "false" @default.
• W82109857 magId "82109857" @default.
• W82109857 workType "article" @default.